Arena Pharmaceuticals, Inc. Provides Corporate Update and Reports Third Quarter 2012 Financial Results
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2012.
Arena is preparing for the launch of BELVIQ® (lorcaserin HCl) in the United States, pursuing regulatory approval and collaborations for BELVIQ in additional territories, and selectively advancing its earlier-stage drug candidates.
Arena is preparing for the launch of BELVIQ® (lorcaserin HCl) in the United States, pursuing regulatory approval and collaborations for BELVIQ in additional territories, and selectively advancing its earlier-stage drug candidates.